Natalizumab for Active Crohn's Disease

2003814 citationsJournal Article

Authors

Subrata Ghosh · Western General Hospital

Eran Goldin · Hadassah Academic College

F. Gordon · University College London

H Malchow · Klinikum Leverkusen

J Rask-Madsen · Herlev Hospital

Paul Rutgeerts

P Vyhnálek · Nemocnice Pardubického Kraje

Abstract

Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease.

Topics & Keywords

Cell Adhesion Molecules Research Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 348, Issue 1, pp. 24-32

DOI: 10.1056/nejmoa020732

Field-Weighted Citation Impact: 30.80